Popular

We are issuing a trade alert on a NASDAQ company we have followed since 2011 that not only is primed to move much higher on the heels of M&A, but could be aided by the near term commencement of a short squeeze.

Fundamentally, company revenue could reach the $14M - $16M range this year, up from a few hundred thousand in 2013 and could achieve $25M+ in revenue next year, aided by recently closed and pending M&A. The stock, which has been the target of naked short selling, is primed to be driven to new levels by short covering in response to pending events, taking the fast-growing company to new highs.

Today we are initiating coverage of a company that might be the perfect answer to a market correction, given its industry and asset class. At its peak, the stock carried a market cap of $200M. Today the dual-listed stock is a fraction of that level yet the model is better than ever. That is why we are projecting a triple from current levels.

I am usually not a fan of sub-penny stocks given the inherent risk they pose. In the case of today’s profiled stock, I was compelled to make an exception. After all, the Company was profitable and posted $3.6 million in sales last year (up from $2.3M in 2010) and has a much higher gross margin than any of its competitors, including the publicly traded industry leader. It doesn’t hurt that its extremely low valuation of .3x its 2013 sales means it has room to move higher and could get a boost from the execution of its own M&A down the road.

BioCorRx may have developed the holy grail of alcohol treatment, known as the Start Fresh Program, which is used by clinics across the country.The Company’s business model should result in major operating profits beginning next year as meaningful market penetration occurs.

We don’t issue more than 2 or 3 trading alerts in any given year and this is our first of 2014, so rest assured that we are highly confident that a quick 40% return is in the cards. Check out the thumbnail sketch of this unusual opportunity.

This stock is clearly oversold at current levels and with an expected resurgence in new business, as evidenced by yesterday’s news; we expect the stock to double from here in the near term. In our view, the business model is sound and management is in the early innings of the execution phase of that model. As a result, the current share price illustrates little risk and big upside.